John Kirkwood
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, John Kirkwood sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
John Kirkwood: 8 sponsored US clinical trials, 2 recruiting.
John Kirkwood sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced Melanoma, with 1 trials.
Upper-quartile sponsor footprint
John Kirkwood sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
NCT06599619
Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma
NCT07631325
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT04688658
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
NCT03743766
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
NCT01943422
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
NCT01568996
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
NCT01042366
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the John Kirkwood pipeline
2 recruiting of 8 indexed (25% open); 3 completed (38%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Locally Advanced Melanoma (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
John Kirkwood: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
John Kirkwood sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this John Kirkwood page
8 registered trials is a research-attention snapshot, not an endorsement of John Kirkwood or any single study.
- 2 of John Kirkwood's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Locally Advanced Melanoma is the condition John Kirkwood studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. John Kirkwood pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.